Physicians - maximum of 0.25 AMA PRA Category 1 Credit(s)™
ABIM Diplomates - maximum of 0.25 ABIM MOC points
Nurses - 0.25 ANCC Contact Hour(s) (0 contact hours are in the area of pharmacology)
Physician Assistant - 0.25 AAPA hour(s) of Category I credit
IPCE - 0.25 Interprofessional Continuing Education (IPCE) credit
This activity is intended for hematologists/oncologists, dermatologists, internists, nurses, family medicine/primary care clinicians, physician assistants, and other members of the health care team caring for patients with low-risk melanoma.
The goal of this activity is for learners to be better able to describe subsets of patients with melanoma with very low risk for death, based on an analysis of classification and regression tree and logistic regression models, using data from the US Surveillance, Epidemiology, and End Results database.
Upon completion of this activity, participants will:
Medscape, LLC requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.
All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated. Others involved in the planning of this activity have no relevant financial relationships.
This activity was planned by and for the healthcare team, and learners will receive 0.25 Interprofessional Continuing Education (IPCE) credit for learning and change.
Medscape, LLC designates this enduring material for a maximum of 0.25
AMA PRA Category 1 Credit(s)™
. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.25 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
Awarded 0.25 contact hour(s) of nursing continuing professional development for RNs and APNs; 0.00 contact hours are in the area of pharmacology.
Medscape, LLC has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 0.25 AAPA Category 1 CME credits. Approval is valid until 01/27/2024. PAs should only claim credit commensurate with the extent of their participation.
For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]
There are no fees for participating in or receiving credit for this online educational activity. For information on applicability
and acceptance of
continuing education credit for this activity, please consult your professional licensing board.
This activity is designed to be completed within the time designated on the title page; physicians should claim only those
credits that reflect the
time actually spent in the activity. To successfully earn credit, participants must complete the activity online during the
valid credit period that
is noted on the title page. To receive
AMA PRA Category 1 Credit™, you must receive a minimum score of 75% on the post-test.
Follow these steps to earn CME/CE credit*:
You may now view or print the certificate from your CME/CE Tracker. You may print the certificate but you cannot alter it.
Credits will be tallied in
your CME/CE Tracker and archived for 6 years; at any point within this time period you can print out the tally as well as
the certificates from the
CME/CE Tracker.
*The credit that you receive is based on your user profile.
CME / ABIM MOC / CE Released: 1/27/2023
Valid for credit through: 1/27/2024, 11:59 PM EST
processing....
Melanoma is the most prevalent potentially fatal skin cancer, but prognosis is very good for American Joint Committee on Cancer (AJCC) stage T1 disease. Prognostic modeling can predict survival in patients with melanoma and identify prognostic variables.
AJCC staging uses Breslow thickness and primary tumor ulceration. Mitotic rate, Clark levels of invasion III and greater, and tumorigenicity or vertical growth phase also strongly correlate with poorer outcomes.
Although melanoma is the most serious skin cancer, most patients do have high chances of survival. New research has now identified a subset of patients with early disease who have a very low risk of dying from the disease.
In a cohort of almost 11,600 patients, the overall 7-year rate of death from melanoma was 2.5%, but the risk in a subset of 25% of patients was below 1%.
Conversely, the study authors were also able to identify a small subset of high‐risk patients with a greater than 20% risk for death.
Although more data are needed and the findings should be verified in other studies, the use of a different term such as “melanocytic neoplasms of low malignant potential,” rather than “melanoma,” may be more appropriate and may help to begin to address the problem of overdiagnosis, the authors note.
“While the topic of very low risk melanomas has been presented at national and international meetings, there have been no formal discussions to define the classification of ‘melanocytic neoplasms of low malignant potential’ at this time,” first author Megan M. Eguchi, MPH, from the Department of Medicine, University of California, Los Angeles, said in an interview. “Criteria would need to be established using study designs beyond those available using [Surveillance, Epidemiology, and End Results (SEER)] data.”
She emphasized that at this time, they do not propose any change to treatment of these lesions, just a change to the terminology.
The study was recently published online in Cancer.
Even though melanoma is considered to be the most common potentially lethal tumor of the skin, prognosis is often very good for those with T1 tumors--those in the lowest risk category. Prognostic modeling has been used to predict survival in patients with melanoma and to identify prognostic variables, the authors note, with the most prominent attributes being Breslow thickness and ulceration of the primary tumor, which form the basis of the current AJCC staging system.
There is evidence that the increasing incidence of melanoma is partly a result of overdiagnosis, meaning the diagnosis of lesions that will not lead to symptoms or death. The authors write that they were interested in identifying lesions that are currently diagnosed as melanoma but might lack the capacity for metastasis--cases that could potentially be part of the phenomenon of overdiagnosis.
Subsets With Low and High Risk for DeathIn the study, Dr Eguchi and colleagues analyzed information from the SEER database and identified 11,594 patients who were diagnosed in 2010 and 2011 with stage 1 melanoma that was 1.0 mm in thickness or smaller and had not spread to the lymph nodes. Prognostic models for risk for death from melanoma in patients with low-risk melanomas were developed, and then the ability of the models to identify very low risk subsets of patients with melanoma‐specific survival surpassing that of T1 overall was evaluated.
The median age of the patients was 58 years, the median Breslow thickness was 0.45 mm (interquartile range [IQR], 0.30-0.65 mm), and 71% were assigned stage IA. Ulceration was present in 4% of cases, 27% were mitogenic, and 45% were Clark level II, and within this cohort, 292 (2.5%) patients died of melanoma within 7 years. In the training data set, 177 (2.3%) of 7652 patients died of melanoma within 7 years; numbers were similar in the testing set (115 of 3942; 2.9%).
Overall, the investigators identified 3 large subsets of patients who were in the AJCC 7th edition classification for stage I (“thin”) melanoma, who had a risk for death of approximately less than 1%. This was a marked improvement from the rate of the overall sample. In the simplest model (model 1A), patients who were younger than 70 years at diagnosis with Clark level II invasion were deemed at very low risk.
In model 1B the same initial classification was used, but it was further refined and limited to patients who were either aged 43 years or younger or aged 44 to 69 years with Breslow thickness less than 0.40 mm. At 10 years postdiagnosis this subset also showed a less than 1% risk for death from melanoma. The logistic regression model (model 2) was similar, as it identified about 25% of patients with a predicted risk for death of less than 0.5%, incorporating patient age, sex, mitogenicity, Clark level, and ulceration. Model 2 was also able to further identify a small subset of patients with no deaths.
The logistic regression model was also able to identify a very small subset (0.7% and 0.8%) of patients who had a risk for death that exceeded 20%, which was markedly higher compared with that of most patients with T1b tumors.
More Data NeededCommenting on the study, Beth Goldstein MD, a dermatologist and cofounder of Modern Ritual Health, Chapel Hill, North Carolina, noted that in the future, when there is the ability to determine which lesions have an aggressive biologic potential, “then ideally, we can avoid unnecessary removals.”
Dr Goldstein acknowledged that there are unnecessary procedures performed perhaps for lesions that would never become life threatening, but at the same time, it is known that there are certain early lesions that are more likely to metastasize and are only known after a complete removal and pathologic assessment.
In addition, besides concerns with removing a suspicious lesion, such as scarring, “there is very limited morbidity associated with this procedure,” she said. “Most patients with early melanomas do not require more than an outpatient procedure under local anesthetic and are already reassured of the low-risk nature of their early melanoma.”
At this time, “we do not have the ability to differentiate these tumors further from the initial assessment,” Dr Goldstein continued. “While there is an ability to screen melanomas for higher likelihood for metastasis with the 31 genetic expression profile test, there is still much work to be done to refine these resources.”
This study was supported by National Cancer Institute. Dr Eguchi and Dr Goldstein have disclosed no relevant financial relationships.
Cancer. November 7, 2022.[1]